CSRC approves Changyu Group's application for an IPO on the Shanghai Stock Exchange Main Board.
On January 9th, the China Securities Regulatory Commission issued the "Approval for the Initial Public Offering of Shares by Changyu Holdings Group Limited".
On January 9th, the China Securities Regulatory Commission issued the reply on approving the initial public offering of shares by Chongyang Holdings Group Co., Ltd. It is reported that Chongyang Group plans to be listed on the Shanghai Stock Exchange main board, with Southwest as its sponsoring institution, aiming to raise 700 million yuan.
According to the prospectus, Chongyang Group is mainly engaged in research, development, production, and sales of zirconium products, special nylon products, and fine chemical products. Its main products include zirconium oxychloride, zirconium carbonate, zirconium oxide, nano composite zirconium oxide, special nylon, long carbon chain diacids, long carbon chain diols, and long carbon chain dimethyl ester.
The company's products are widely used in sectors such as automotive, communications, consumer electronics, high-performance ceramics, and medical fields. The company has established a relatively complete sales network and service system, with its products sold in mainland China, Europe, the United States, Japan, South Korea, India, Southeast Asia, and other countries and regions. Zirconium products and special nylon products are the main sources of the company's revenue and profits.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


